SR spoke of ‘where we are” compared with “where we should be”.
In terms of where we are, he said the “entire category” was currently limited to 1.7 million patients because of the way that the category has evolved over the past 30 years (roughly how long ago the first dermal regeneration product was approved by the FDA).
In terms of where we should be, he thinks that we should be seeing surgical procedures that impact 10 million patients' lives.
Exactly what is meant by "entire category" is unclear. What is clearer is the fundamental ambition to grow surgical procedures in this category by six-fold.
SR spoke of ‘where we are” compared with “where we should be”....
-
- There are more pages in this discussion • 31 more messages in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)
Add PNV (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
$2.43 |
Change
-0.090(3.57%) |
Mkt cap ! $1.678B | |||
| Open | High | Low | Value | Volume |
| $2.49 | $2.50 | $2.43 | $2.311M | 940.0K |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 3 | 17100 | $2.43 |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| $2.45 | 5973 | 1 |
View Market Depth
| Last trade - 16.10pm 04/10/2024 (20 minute delay) ? |
| PNV (ASX) Chart |